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Abstract A 54-year-old HIV-negative patient suffering frOIn
T -cell lytnphoIna of Lennert's lytnphoIna (Lel)
type was treated for 13 Inonths with interferon a-
2b. While on treatment with interferon the patient
derrlOnstrated suppression of total and CD4+ lytn-
phocytes to levels < 0,5 and 0,2 x 10911, respectively.
Although interferon was successful in controlling
the lytnphoIna the clinical course was complicated
by the rapid development of aggressive, fatal
Kaposi's sarCOIna shortly after cessation of inter-
feron treatment.
It is suggested that the immunosuppressive
effect of interferon therapy (or the T -cell lym-
phoma or both) may have played a role in the
development of Kaposi's sarCOIna as a second
malignancy.
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TIe use of interferons has led to a number ofimmunological disturbances, usually auto-immune in nature. I,' We report here the occur-
rence of rapidly growing Kaposi's sarcoma in a patient
being treated for a T-cell lymphoma (Lennert's lym-
phoma) with recombinant a-interferon. Certain aspects
of the apparently paradoxical effects of a-interferon
action may be relevant to the pathogenesis of this condi-
tion.
Case report
A 45-year-old woman presented in October 1982 with
bitonsillar enlargement of recent onset. Biopsy disclosed
a malignant lymphoma with morphological and
immunohistological features consistent with aT-cell
lymphoma of the Lennert's (Lel) type (Fig. 1). Initial
staging revealed only localised tonsillar involvement.
Treatment comprised six cycles of combination
chemotherapy, which was stopped in July 1983 after the
patient had shown a full clinical response.
In 1985 there was a relapse of the lymphoma with
generalised lymphadenopathy together with systemic
symptoms. Further chemotherapy again led to regres-
sion of nodes. After clinical response chemotherapy was
again discontinued in March 1986.
A third relapse in 1987 was accompanied by
retroperitoneal lymph nodes as well as a cutaneous ulcer
in the sacral region. Biopsy again showed the presence
of Lel, with more florid epithelioid cell reaction than
before. Screening for HIV by enzyme-linked immuno-
sorbent assay (EUSA) was negative.
In December 1987 the patient was started on treat-
ment with interferon a-2b (Intron; Scherag) 1,5 x 106
units daily by subcutaneous injection. Over the next few
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FIG. 1.
Biopsy of the tonsil (October 1982) shows replacement of
the tonsil by an abnormal infiltrate comprising small to
intermediate-sized lymphoid cells with a slight irregularity
to their nuclear outline. There is a florid epithelioid histio-
cytic response (H and E, original magnification x 400).
weeks the lymphadenopathy and systemic symptoms
completely disappeared. During interferon therapy a
significant decline in the total Iymphocyte count, from
no=allevels to 0,5 x 109/1, as well as moderate granulo-
cytopenia (1,5 x 109/1) were noted. This suppression
persisted throughout the period of interferon treatment.
CD4+ counts were consistently < 0,2 x 109/1 throughout
the period of interferon therapy.
At restaging of the lymphoma 13 months after initia-
tion of interferon therapy there was no evidence of resi-
dual disease. Interferon therapy was stopped but 4
weeks later the patient presented again with fever, exten-
sive herpes labialis and oral and oesophageal candidiasis.
In addition there was supraclavicular lymphadenopathy
and palpable splenomegaly (4 cm below the costal mar-
gin). Laboratory studies showed a haemoglobin concen-
tration of 9,5 g/dl, a leucocyte count of 5,1 x 109/1 and a
thrombocyte count of 130 x 109/1. Computed tomo-
graphy (Cn of the abdomen again revealed retroperi-
toneal lymphadenopathy. Investigation for HIV by
means of ELISA and Western blot assay was again
negative.
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Biopsy of the supraclavicular mass revealed this to be
a soft-tissue deposit, rather than a lymph node, showing
histological features of Kaposi's sarcoma (Fig. 2). _0
lymphoma was evident in this biopsy nor at full restag-
ing, which included bone marrow trephine biopsy.
Despite treatment with broad-spectrum antibiotics, anti-
fungal and antiviral agents as well as re-introduction of
a-interferon, the patient's condition deteriorated and
she died of sepsis and multi-organ failure in May 1989.
FIG. 2.
Biopsy of soft-tissue tumour deposit showing involve-
ment by Kaposi's sarcoma. The vascular component of
the tumour is prominent (H and E, original magnification
x 400).
Discussion
Lel has only fairly recently been recognised as a speci-
fic entity with histogenetic origin from peripheral T-
Iymphocyres. ',4
Diagnosis of the condition is complicated by the
presence of a reactive cellular component presumably
induced by the secretion of Iymphokines by the malig-
nant T -cells. Immunocytochemical studies are impor-
tant in confirming the diagnosis. The patient described
here had all the morphological and immunocytochemi-
cal features of Lennert's lymphoma.
Therapy of the peripheral T-celllymphomas has not
been well standardised. Some patients appear to achieve
remission with aggressive chemotherapy but treatment
failure or relapse after initial response to chemotherapy
is not infrequent. This was the case in the patient
described here. A therapeutic trial of interferon resulted
in a good clinical response that lasted for over 13
months but within 4 weeks of the interferon treatment
being stopped the clinical course was complicated by a
rapidly developing, aggressive Kaposi's sarcoma.
Kaposi's sarcoma is often associated with underlying
immunosuppressed srates, including organ transplanta-
tion, auto-immune illnesses and AIDS.'" Since inter-
feron treatment has been the mainsray of systemic thera-
py of Kaposi's sarcoma in these patients the occurrence
of Kaposi's sarcoma in our patient so shortly after inter-
feron therapy would appear to be paradoxical but may
be related to the diverse regulatory effects of the inter-
ferons which are both immunomodulatory as well as
antiproliferative. Among the immunomodulatory activi-
ties the effect on natural killer (1'-TK) cells has received
most attention. While a number of studies have shown a
significant enhancement of 1\.TK cell activity with the use
of natural interferons,8 decreased 1\.TK cell activity has
also been described as well as more generalised immune
suppression.9,10 The differences observed in various stud-
ies may be dependent, among other factors, on the srate
of IT<. cell activity before treatinent as well as on the
dose and source of interferon and the duration of treat-
ment" The direct antiproliferative effects of interferons,
which are not confined only to malignant cells but
which also suppress the proliferation of normal
haemopoietic precursors, causing granulocytopenia and
lymphopenia with resulting immune suppression, may
also be of importance. lo Interferon therapy appears
clearly to have been effective in suppressing the growth
of the T -cell lymphoma in this patient. Since it appears
unlikely that the Kaposi sarcoma appeared de novo dur-
ing the 4-week interval during which interferon was dis-
continued, interferon treatment appears not to have pre-
vented tumorigenesis, and indeed, by virtue of the
reduction of CD4+ Iymphocyres, may have contributed
to the development of the Kaposi sarcoma.
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